Adamis Pharmaceuticals Profit Margin

The latest profit margin for ADMP is -91.28% as of September 2023. That compares with 803.94% in the prior-year period — down 111.4% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Adamis Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ADMP's profit margin moved from 803.94% to -91.28% — a 111.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adamis Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, ADMP currently prints -91.28% for profit margin, while the sector average sits near 13.89%. That is roughly 757.2% below the sector mean. Large gaps often invite a closer look at Adamis Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Adamis Pharmaceuticals converts resources into returns. At -91.28%, ADMP may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 803.94% in the prior-year period — down 111.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ADMP's profit margin (-91.28%), review year-over-year change from 803.94%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.